594 related articles for article (PubMed ID: 26239982)
1. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
2. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
4. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
[TBL] [Abstract][Full Text] [Related]
5. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
[TBL] [Abstract][Full Text] [Related]
6. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Buckner FS; Bahia MT; Suryadevara PK; White KL; Shackleford DM; Chennamaneni NK; Hulverson MA; Laydbak JU; Chatelain E; Scandale I; Verlinde CL; Charman SA; Lepesheva GI; Gelb MH
Antimicrob Agents Chemother; 2012 Sep; 56(9):4914-21. PubMed ID: 22777048
[TBL] [Abstract][Full Text] [Related]
8. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
9. Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection.
Bisio MMC; Jurado Medina LS; García-Bournissen F; Gulin JEN
Parasitol Res; 2024 Jun; 123(6):248. PubMed ID: 38904688
[TBL] [Abstract][Full Text] [Related]
10. Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease.
García MC; Ponce NE; Sanmarco LM; Manzo RH; Jimenez-Kairuz AF; Aoki MP
Antimicrob Agents Chemother; 2016 Jun; 60(6):3700-8. PubMed ID: 27067322
[TBL] [Abstract][Full Text] [Related]
11. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
Diniz LF; Mazzeti AL; Caldas IS; Ribeiro I; Bahia MT
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555633
[TBL] [Abstract][Full Text] [Related]
12. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
Cevey ÁC; Mirkin GA; Penas FN; Goren NB
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
[TBL] [Abstract][Full Text] [Related]
13. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.
Bahia MT; Nascimento AF; Mazzeti AL; Marques LF; Gonçalves KR; Mota LW; Diniz Lde F; Caldas IS; Talvani A; Shackleford DM; Koltun M; Saunders J; White KL; Scandale I; Charman SA; Chatelain E
Antimicrob Agents Chemother; 2014 Aug; 58(8):4362-70. PubMed ID: 24841257
[TBL] [Abstract][Full Text] [Related]
14. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
15. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
[TBL] [Abstract][Full Text] [Related]
17. Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.
Novaes RD; Sartini MV; Rodrigues JP; Gonçalves RV; Santos EC; Souza RL; Caldas IS
Antimicrob Agents Chemother; 2016 Jun; 60(6):3355-64. PubMed ID: 27001816
[TBL] [Abstract][Full Text] [Related]
18. Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection.
Dos Santos FM; Caldas S; de Assis Cáu SB; Crepalde GP; de Lana M; Machado-Coelho GL; Veloso VM; Bahia MT
Exp Parasitol; 2008 Dec; 120(4):385-90. PubMed ID: 18823980
[TBL] [Abstract][Full Text] [Related]
19. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
[TBL] [Abstract][Full Text] [Related]
20. Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection.
Santos DM; Martins TA; Caldas IS; Diniz LF; Machado-Coelho GL; Carneiro CM; Oliveira Rde P; Talvani A; Lana M; Bahia MT
Acta Trop; 2010 Feb; 113(2):134-8. PubMed ID: 19854145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
